We discussed the differential diagnosis of Raynaud's:
- Primary (younger age of onset, symmetrical, tend to be female, no ulcers/pitting, predictable and frequent attacks)
- Secondary
- Trauma (i.e. jack hammer operators)
- Collagen Vascular Associated - Scleroderma, SLE, MTCD (Scleroderma + SLE + myositis overlap), less likely in Sjogren's and RA
- Secondary to vascultitis (i.e. Berger's disease)
- Paraneoplastic (ovarian cancer, angioblastic lymphoma)
- Vascular - peripheral vascular disease
- Drugs (b-blockers, ergotamine, interferons, PVCs)
- Hyperviscosity (Waldenstroms, cryoglobulinemia (HepC), cryofibrinogenemia, cold agglutinins, polycythemia)
- Endocrine (carcinoid, pheo, hypothyroidism)
- Avoid precipitants (keep warm, pre-warm hands before going outside, avoid drugs that worsen)
- Calcium Channel Blockers (i.e. verapamil, amlodipine) or ARBs (losartan)
- Topical nitrates
- As above
- Analgesia
- Topical/Intravenous nitrates
- Limited evidence for prostaglandin, NO, sildenafil, epoprostinol
C = calcinosis of digits from infarcts
R = raynaud's
E = esophogeal reflux
S = sclerodactaly
T = telangectasia
10-15% of people with limited scleroderma will unfortunately develop pulmonary hypertension, which is the complication that is likely to cause significant morbidity and mortality. These patients should be screened yearly with PFT (with DLCO) and 2D echo and pulmonary hypertension should be treated.
Patients with diffuse disease tend to get other end organ complications including pulmonary fibrosis (and secondary pulmonary hypertension) which, once established cannot really be treated. We quickly touched upon the treatment of early pulmonary fibrosis with cyclophosphamide.